Previous 10 | Next 10 |
Summary BNGO reported preliminary Q4 results, showing acceptable core business performance. Aggressive expansion into capital-intensive markets could put significant pressure on BNGO's balance sheet. Recently-introduced LDTs will likely have a limited impact on revenue growth. ...
Guardant Health ( NASDAQ: GH ) said that the U.S. Food and Drug Administration (FDA) approved its Guardant360 CDx liquid biopsy test as a companion diagnostic for use with Menarini's medicine Orserdu. Guardant360 can be used now to identify patients with advan...
ESR1 mutations, a known driver of resistance to standard endocrine therapy, are present in up to 40% of ER+, HER2- advanced breast cancers 1 ORSERDU (elacestrant) is first FDA-approved endocrine therapy innovation in more than 20 years, specifically addressing ESR1 mutations, a major ...
Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Multi Cap Growth Strategy takes a concentrated,...
Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. The Aggressive Growth Strategy follows a focused, h...
Summary Harnessing the power of a simple blood test (i.e., liquid biopsy), Guardant Health has offered hope for patients through early detection of cancer. Revenues are growing robustly while there are other catalysts to catapult future growth. The company recently reported positive...
Trial will evaluate use of circulating tumor DNA to guide chemotherapy treatment decisions following surgery for stage II-III colorectal cancer patients based on test results for minimal residual disease with Guardant Reveal™ blood test Study involving approximately 40 sites and 16...
Summary NVTA Q4 cash balance remained flat year-over-year at $555M, with 2022 revenue declining by $4M to $122M. Shares appreciated 25% after last week's Q4 purview on optimism over management's ability to trim operating costs, which would provide NVTA with sufficient runway to execute ...
Presentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers and predict disease recurrence and response to therapy Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data f...
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. RED DEER, AB / ACCESSWIRE / January 16, 2023 / Gamehost Inc. (‘Gamehost', the ‘Company') (TSX:GH) Gamehost has declared a cash dividend for the month of January 2023 of $0.03 (CDN) per com...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...